QURE uniQure N.V.
Financings ·
uniQure filed a $150,000,000 offering on June 22, 2026 and priced an upsized deal on June 23. The FDA has said its Huntington's data are not sufficient evidence for a marketing application, and the proceeds are partly earmarked for a launch.
uniQure amended its Hercules term loan on September 22, 2025. The 2025 Term Loan is up to $175 million, $50 million was drawn at closing to refinance existing debt, and the balance depends on milestones tied to AMT-130.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $140.7 million | $143.8 million |
| Net income (loss) | -$199.0 million | -$239.6 million |
| Cash from operations | -$178.0 million | -$182.7 million |
| Cash and equivalents | $80.2 million | $158.9 million |
Our latest story on this, dated Jun 22, 2026: "uniQure launches $150,000,000 offering, then prices an upsized $225 million sale". The story links the filing or release it is based on. Read the story.
uniQure N.V. trades under the ticker QURE on NASDAQ.
uniQure N.V. is listed on NASDAQ. Our directory also records these other listings: BMV:QURE/N; FWB:UQ1; GETTEX:UQ1; HAM:UQ1; HAN:UQ1; LS:A1XDTV; LSE:0EE0; LSX:A1XDTV; SWB:UQ1; TRADEGATE:UQ1; XETR:UQ1.
The SEC Central Index Key (CIK) for uniQure N.V. is 1590560. Its filings are on SEC EDGAR.
Our directory records uniQure N.V. under Netherlands.
Our directory classifies uniQure N.V. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for uniQure N.V. is NL0010696654.
aibio.space lists uniQure N.V. among 2,820 public biotech companies and publishes its news here as stories appear.
uniQure N.V. reported a net loss of $199.0 million for the fiscal year ended Dec 31, 2025, and used $178.0 million of cash in operations, per its annual report to the SEC.
$140.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
$140.0 million in cash at Mar 31, 2026, per its 10-Q.
Our latest story on uniQure, dated Jun 22, 2026: "uniQure launches $150,000,000 offering, then prices an upsized $225 million sale". uniQure filed a $150,000,000 offering on June 22, 2026 and priced an upsized deal on June 23. The FDA has said its Huntington's data are not sufficient evidence for a marketing application, and the proceeds are partly earmarked for a launch. Source.
Our latest debt story, dated Sep 24, 2025: "uniQure amends Hercules term loan and draws $50 million to refinance debt". uniQure amended its Hercules term loan on September 22, 2025. The 2025 Term Loan is up to $175 million, $50 million was drawn at closing to refinance existing debt, and the balance depends on milestones tied to AMT-130. Source.
From our story of Sep 24, 2025: The 10-K, written before this loan amendment, says net proceeds from a follow-on share offering that raised $70.1 million, together with existing cash, cash equivalents and investments, will fund operations into the second half of 2027. Source.
We do not publish live share prices. In its annual report, uniQure N.V. put the market value of shares held by non-affiliates (public float) at $764.8 million as of Jun 30, 2025.
Reported a financing. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio